Congress Introduces SAFE Drugs Act of 2025, Expanding FDA Oversight of Compounded GLP-1 Drugs and Telehealth Providers - Dykema
The SAFE Drugs Act of 2025 expands FDA oversight of compounded GLP-1 drugs and telehealth providers, imposing new cGMP requirements and registration mandates for 503B outsourcing facilities.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Compounding outsourcing facilities (503B) and telehealth providers involved in GLP-1 drug compounding should confirm how it applies to their specific situation before acting. There is a time constraint attached: Effective upon enactment; compliance expected within 90 days of passage.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA now requires 503B facilities compounding GLP-1 drugs to comply with enhanced cGMP standards, register with FDA, and report adverse events; telehealth providers must verify patient prescriptions and adhere to new telemedicine rules.
Who it affects
Compounding outsourcing facilities (503B) and telehealth providers involved in GLP-1 drug compounding
What you must do
Review current compounding practices for GLP-1 drugs, update cGMP protocols, register with FDA if not already, and implement telehealth compliance measures.
Deadline
Effective upon enactment; compliance expected within 90 days of passage.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- Determination That RECTIV (Nitroglycerin) Ointment, 0.4%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Determination That Prednisolone Tablet, 5 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Determination That VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9%, Injection, 50 units/50 milliliters (1 unit/milliliters) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness